| Biomarker ID | 1459 |
| PMID | 25032132 |
| Year | 2014 |
| Biomarker | Vascular Endothelial Growth Factor (VEGF) + Prostate Specific Antigen (PSA) |
| Biomarker Basis | Concentration Based (VEGF: pg/mL; PSA: ng/mL) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa: [VEGF+ PSA] |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 35 (95% CI: 6.3-194.2) |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs (Benign prostatic hyperplasia + Healthy Individuals) |
| Type of Biomarker | Diagnostic |
| Cohort | 47 patients with Prostate Cancer, 57 with Benign prostatic hyperplasia (BPH) and 57 healthy individuals were selected for the study |
| Senstivity | 91% |
| Specificity | 87% |
| AUC | 0.876 |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |